$0.54
+0.04 (+8.79%)
Open$0.50
Previous Close$0.49
Day High$0.54
Day Low$0.48
52W High$11.04
52W Low$6.33
Volume—
Avg Volume102.9K
Market Cap7.14M
P/E Ratio21.63
EPS$0.45
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,155.6% upside
Current
$0.54
$0.54
Target
$12.09
$12.09
$6.99
$12.09 avg
$15.02
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.42M | 3.23M | 3.00M |
| Net Income | -386,907 | -351,594 | -373,147 |
| Profit Margin | -11.3% | -10.9% | -12.5% |
| EBITDA | -622,705 | -634,407 | -526,103 |
| Free Cash Flow | -366,603 | -274,517 | -229,625 |
| Rev Growth | +21.7% | +15.6% | +5.5% |
| Debt/Equity | 0.38 | 0.31 | 0.42 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |